Our results demonstrate the specificity and ability of BR2-PRPPD peptides to inhibit EGF signaling, NSCLC cell growth inhibition, and provide a promising anticancer peptide for NSCLC treatment. Here, EGF is linked to non-small cell lung carcinoma.